CSL delivered a messy result. Although they did say they are on track to achieve FY guidance, gross margins and 1H adjusted ...

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth forecasts in maintaining positive views ...

In a report released today, Steven Wheen from Jarden maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of A$314.37.

CSL Limited is one of the world’s leading companies specializing in blood plasma therapies, nephrology, and vaccines. The ...

But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We have found that the best way to discover great value opportunities is to pair a ...

The City of Côte St. Luc and Mandevco, the developer of Quartier Cavendish, are not yet agreed on the city’s position ...

CSL Behring has shared positive four-year results from a late-stage study of its haemophilia B gene therapy Hemgenix ...

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

List today: Ares Management Corporation ARES is an alternative asset manager. The Zacks Consensus Estimate for its current year earnings has been revised 5.4% downward over the last 60 days. CSL ...

CSL’s shares (ASX: CSL) have started the year with the bears leading the way, with a 0.26% decline today bringing the cumulative YTD loss to 8.86%. With a new 52 week low of $253.04 being hit on the ...